AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort

BackgroundSystemic lupus erythematosus (SLE) is an idiopathic autoimmune disease associated with significant co-morbidity, affecting both quality of life, but also life expectancy. In most of the cases, disease course and treatment have an important contribution to accumulation of damage. This is wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.1092-1093
Hauptverfasser: Saulescu, I., Gudu, T., Opris, D., Borangiu, A., Groseanu, L., Ionescu, R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1093
container_issue Suppl 2
container_start_page 1092
container_title Annals of the rheumatic diseases
container_volume 74
creator Saulescu, I.
Gudu, T.
Opris, D.
Borangiu, A.
Groseanu, L.
Ionescu, R.
description BackgroundSystemic lupus erythematosus (SLE) is an idiopathic autoimmune disease associated with significant co-morbidity, affecting both quality of life, but also life expectancy. In most of the cases, disease course and treatment have an important contribution to accumulation of damage. This is way, for patients with SLE it is important to obtain control of disease activity, but also to prevent irreversible organ damage.ObjectivesWe performed a prospective, observational study aiming to evaluate possible factors related to damage accrual in a roumanian SLE cohort.MethodsThis study included 65 patients diagnosed with SLE according to ACR 1997 classifications criteria. They were evaluated according to an established protocol in order to obtain relevant data about disease history, disease activity and damage accumulated from the beginning of SLE. For this purpose, we obtained immunological profile for all patients; we recorded all relevant laboratory data connected to organ involvement in SLE and applied scores like SELENA-SLEDAI – to evaluate activity - and SLICC/ACR damage index (SDI). In order to be able to apply SDI to all patients, one of the inclusion criteria was the disease older then 1 year. All patients had an evaluation of their status for 25(OH) Vitamin D.ResultsStudy group had a female predominance (93.84%), with a mean age of 42.45 [15.859] and a mean disease duration of 8.0 [7.7] years. The mean SELENA-SLEDAI score was 5.37 [3.385]. Mean prednisone equivalent dose was 7.45 [8.38] daily. More then half of the patients (34 from 65) had a SDI equal or more than 1. When compared between the one that already accumulated damage (SDI≥1) with the others, significant differences (p
doi_str_mv 10.1136/annrheumdis-2015-eular.4808
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901779013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322502003</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1273-9d940b1b33b552fdc8fbdc94486ae09402f8ccdbbab59b8c06a268606275f9e63</originalsourceid><addsrcrecordid>eNqVkMtOwzAQRS0EEqXwD5a6TrHzcByxKoUCUiWkAktkjR2Hpkri4seiOzb8KF-CS1mwZTOjO3PvjHQQmlAypTRjlzAMdq1DX7cuSQktEh06sNOcE36ERjRnPI4ZOUYjQkiW5BUrT9GZc5soCad8hF5n16Qo2dfH5wKUN9bhle7A6xp7g2-ghzeNZ0rZAB1uBwx4ZUIPQwsDfto5r_tW4WXYBodv7c6vdQ_euKjmZm2sP0cnDXROX_z2MXpZ3D7P75Pl493DfLZMJE3LLKnqKieSyiyTRZE2teKNrFWV55yBJnGXNlypWkqQRSW5IgxSxhlhaVk0lWbZGE0Od7fWvAftvNiYYIf4UtCK0LKMJYuuq4NLWeOc1Y3Y2rYHuxOUiD1P8Yen2PMUPzzFnmdMs0Na9pt_Bb8BG0aCFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901779013</pqid></control><display><type>article</type><title>AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort</title><source>BMJ Journals - NESLi2</source><creator>Saulescu, I. ; Gudu, T. ; Opris, D. ; Borangiu, A. ; Groseanu, L. ; Ionescu, R.</creator><creatorcontrib>Saulescu, I. ; Gudu, T. ; Opris, D. ; Borangiu, A. ; Groseanu, L. ; Ionescu, R.</creatorcontrib><description>BackgroundSystemic lupus erythematosus (SLE) is an idiopathic autoimmune disease associated with significant co-morbidity, affecting both quality of life, but also life expectancy. In most of the cases, disease course and treatment have an important contribution to accumulation of damage. This is way, for patients with SLE it is important to obtain control of disease activity, but also to prevent irreversible organ damage.ObjectivesWe performed a prospective, observational study aiming to evaluate possible factors related to damage accrual in a roumanian SLE cohort.MethodsThis study included 65 patients diagnosed with SLE according to ACR 1997 classifications criteria. They were evaluated according to an established protocol in order to obtain relevant data about disease history, disease activity and damage accumulated from the beginning of SLE. For this purpose, we obtained immunological profile for all patients; we recorded all relevant laboratory data connected to organ involvement in SLE and applied scores like SELENA-SLEDAI – to evaluate activity - and SLICC/ACR damage index (SDI). In order to be able to apply SDI to all patients, one of the inclusion criteria was the disease older then 1 year. All patients had an evaluation of their status for 25(OH) Vitamin D.ResultsStudy group had a female predominance (93.84%), with a mean age of 42.45 [15.859] and a mean disease duration of 8.0 [7.7] years. The mean SELENA-SLEDAI score was 5.37 [3.385]. Mean prednisone equivalent dose was 7.45 [8.38] daily. More then half of the patients (34 from 65) had a SDI equal or more than 1. When compared between the one that already accumulated damage (SDI≥1) with the others, significant differences (p&lt;0.05) were observed related to more frequent association with renal involvement (p 0.05), presence of antiphospholipidic antibody (p0.001), presence of disease activity (p 0.031) and atherosclerotic vascular disease (p&lt;0.001) in the group with SDI≥1. When compared according to 25(OH) Vitamin D level, more patients from the group with SDI≥1 had levels below 30ng/ml and the difference was significant statistic: p 0.037 for Vitamin D insufficiency (21-30ng/ml) and p 0.016 for vitamin D deficiency (&lt;20ng/ml). Dividing patients according to corthicotherapie duration, SDI≥1 was found more frequent when corticotherapie duration was more than 5 years (p 0.007).ConclusionsIt is well known that damage accrual has a continuum evolution in patients with SLE. Identification of factors related to that gives us the opportunity to slow down this evolution. Prompt treatment of disease activity especially renal flares, screening for association with antiphosholipidic syndrome or atherosclerotic vascular disease will improve evolution in this cases. This data shows that corthicotherapie over treating has an important contribution in damage related to SLE.ReferencesM. Petri et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64(12): 4021-8.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.4808</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1092-1093</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1092.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/1092.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77569,77600</link.rule.ids></links><search><creatorcontrib>Saulescu, I.</creatorcontrib><creatorcontrib>Gudu, T.</creatorcontrib><creatorcontrib>Opris, D.</creatorcontrib><creatorcontrib>Borangiu, A.</creatorcontrib><creatorcontrib>Groseanu, L.</creatorcontrib><creatorcontrib>Ionescu, R.</creatorcontrib><title>AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort</title><title>Annals of the rheumatic diseases</title><description>BackgroundSystemic lupus erythematosus (SLE) is an idiopathic autoimmune disease associated with significant co-morbidity, affecting both quality of life, but also life expectancy. In most of the cases, disease course and treatment have an important contribution to accumulation of damage. This is way, for patients with SLE it is important to obtain control of disease activity, but also to prevent irreversible organ damage.ObjectivesWe performed a prospective, observational study aiming to evaluate possible factors related to damage accrual in a roumanian SLE cohort.MethodsThis study included 65 patients diagnosed with SLE according to ACR 1997 classifications criteria. They were evaluated according to an established protocol in order to obtain relevant data about disease history, disease activity and damage accumulated from the beginning of SLE. For this purpose, we obtained immunological profile for all patients; we recorded all relevant laboratory data connected to organ involvement in SLE and applied scores like SELENA-SLEDAI – to evaluate activity - and SLICC/ACR damage index (SDI). In order to be able to apply SDI to all patients, one of the inclusion criteria was the disease older then 1 year. All patients had an evaluation of their status for 25(OH) Vitamin D.ResultsStudy group had a female predominance (93.84%), with a mean age of 42.45 [15.859] and a mean disease duration of 8.0 [7.7] years. The mean SELENA-SLEDAI score was 5.37 [3.385]. Mean prednisone equivalent dose was 7.45 [8.38] daily. More then half of the patients (34 from 65) had a SDI equal or more than 1. When compared between the one that already accumulated damage (SDI≥1) with the others, significant differences (p&lt;0.05) were observed related to more frequent association with renal involvement (p 0.05), presence of antiphospholipidic antibody (p0.001), presence of disease activity (p 0.031) and atherosclerotic vascular disease (p&lt;0.001) in the group with SDI≥1. When compared according to 25(OH) Vitamin D level, more patients from the group with SDI≥1 had levels below 30ng/ml and the difference was significant statistic: p 0.037 for Vitamin D insufficiency (21-30ng/ml) and p 0.016 for vitamin D deficiency (&lt;20ng/ml). Dividing patients according to corthicotherapie duration, SDI≥1 was found more frequent when corticotherapie duration was more than 5 years (p 0.007).ConclusionsIt is well known that damage accrual has a continuum evolution in patients with SLE. Identification of factors related to that gives us the opportunity to slow down this evolution. Prompt treatment of disease activity especially renal flares, screening for association with antiphosholipidic syndrome or atherosclerotic vascular disease will improve evolution in this cases. This data shows that corthicotherapie over treating has an important contribution in damage related to SLE.ReferencesM. Petri et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64(12): 4021-8.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkMtOwzAQRS0EEqXwD5a6TrHzcByxKoUCUiWkAktkjR2Hpkri4seiOzb8KF-CS1mwZTOjO3PvjHQQmlAypTRjlzAMdq1DX7cuSQktEh06sNOcE36ERjRnPI4ZOUYjQkiW5BUrT9GZc5soCad8hF5n16Qo2dfH5wKUN9bhle7A6xp7g2-ghzeNZ0rZAB1uBwx4ZUIPQwsDfto5r_tW4WXYBodv7c6vdQ_euKjmZm2sP0cnDXROX_z2MXpZ3D7P75Pl493DfLZMJE3LLKnqKieSyiyTRZE2teKNrFWV55yBJnGXNlypWkqQRSW5IgxSxhlhaVk0lWbZGE0Od7fWvAftvNiYYIf4UtCK0LKMJYuuq4NLWeOc1Y3Y2rYHuxOUiD1P8Yen2PMUPzzFnmdMs0Na9pt_Bb8BG0aCFg</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Saulescu, I.</creator><creator>Gudu, T.</creator><creator>Opris, D.</creator><creator>Borangiu, A.</creator><creator>Groseanu, L.</creator><creator>Ionescu, R.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort</title><author>Saulescu, I. ; Gudu, T. ; Opris, D. ; Borangiu, A. ; Groseanu, L. ; Ionescu, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1273-9d940b1b33b552fdc8fbdc94486ae09402f8ccdbbab59b8c06a268606275f9e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saulescu, I.</creatorcontrib><creatorcontrib>Gudu, T.</creatorcontrib><creatorcontrib>Opris, D.</creatorcontrib><creatorcontrib>Borangiu, A.</creatorcontrib><creatorcontrib>Groseanu, L.</creatorcontrib><creatorcontrib>Ionescu, R.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saulescu, I.</au><au>Gudu, T.</au><au>Opris, D.</au><au>Borangiu, A.</au><au>Groseanu, L.</au><au>Ionescu, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>1092</spage><epage>1093</epage><pages>1092-1093</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundSystemic lupus erythematosus (SLE) is an idiopathic autoimmune disease associated with significant co-morbidity, affecting both quality of life, but also life expectancy. In most of the cases, disease course and treatment have an important contribution to accumulation of damage. This is way, for patients with SLE it is important to obtain control of disease activity, but also to prevent irreversible organ damage.ObjectivesWe performed a prospective, observational study aiming to evaluate possible factors related to damage accrual in a roumanian SLE cohort.MethodsThis study included 65 patients diagnosed with SLE according to ACR 1997 classifications criteria. They were evaluated according to an established protocol in order to obtain relevant data about disease history, disease activity and damage accumulated from the beginning of SLE. For this purpose, we obtained immunological profile for all patients; we recorded all relevant laboratory data connected to organ involvement in SLE and applied scores like SELENA-SLEDAI – to evaluate activity - and SLICC/ACR damage index (SDI). In order to be able to apply SDI to all patients, one of the inclusion criteria was the disease older then 1 year. All patients had an evaluation of their status for 25(OH) Vitamin D.ResultsStudy group had a female predominance (93.84%), with a mean age of 42.45 [15.859] and a mean disease duration of 8.0 [7.7] years. The mean SELENA-SLEDAI score was 5.37 [3.385]. Mean prednisone equivalent dose was 7.45 [8.38] daily. More then half of the patients (34 from 65) had a SDI equal or more than 1. When compared between the one that already accumulated damage (SDI≥1) with the others, significant differences (p&lt;0.05) were observed related to more frequent association with renal involvement (p 0.05), presence of antiphospholipidic antibody (p0.001), presence of disease activity (p 0.031) and atherosclerotic vascular disease (p&lt;0.001) in the group with SDI≥1. When compared according to 25(OH) Vitamin D level, more patients from the group with SDI≥1 had levels below 30ng/ml and the difference was significant statistic: p 0.037 for Vitamin D insufficiency (21-30ng/ml) and p 0.016 for vitamin D deficiency (&lt;20ng/ml). Dividing patients according to corthicotherapie duration, SDI≥1 was found more frequent when corticotherapie duration was more than 5 years (p 0.007).ConclusionsIt is well known that damage accrual has a continuum evolution in patients with SLE. Identification of factors related to that gives us the opportunity to slow down this evolution. Prompt treatment of disease activity especially renal flares, screening for association with antiphosholipidic syndrome or atherosclerotic vascular disease will improve evolution in this cases. This data shows that corthicotherapie over treating has an important contribution in damage related to SLE.ReferencesM. Petri et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012; 64(12): 4021-8.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.4808</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1092-1093
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901779013
source BMJ Journals - NESLi2
title AB0576 Factors Related to Damage Accrual in a Roumanian Systemic Lupus Erythematosus Cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A20%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0576%E2%80%85Factors%20Related%20to%20Damage%20Accrual%20in%20a%20Roumanian%20Systemic%20Lupus%20Erythematosus%20Cohort&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Saulescu,%20I.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=1092&rft.epage=1093&rft.pages=1092-1093&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.4808&rft_dat=%3Cproquest_cross%3E4322502003%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901779013&rft_id=info:pmid/&rfr_iscdi=true